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Abstract
Background. Glioblastoma remains a deadly brain cancer with dismal prognosis. Genetic alterations, including
IDH mutations, 1p19q co-deletion status and MGMT promoter methylation have been proven to be prognostic and
predictive to response to treatment in gliomas. In this manuscript, we aimed to correlate other mutations and genetic alterations with various clinical endpoints in patients with IDH-wild-type (IDHwt) glioblastoma.
Methods. We compiled a comprehensive clinically annotated database of IDHwt GBM patients treated at the
Ohio State University Wexner Medical Center for whom we had mutational data through a CLIA-certified genomic
laboratory. We then added data that is publicly available from Memorial Sloan Kettering Cancer Center through
cBioPortal. Each of the genetic alterations (mutations, deletions, and amplifications) served as a variable in univariate and multivariate Cox proportional hazard models.
Results. A total of 175 IDHwt GBM patients with available MGMT promoter methylation data from both cohorts
were included in the analysis. As expected, MGMT promoter methylation was significantly associated with improved overall survival (OS). Median OS for MGMT promoter methylated and unmethylated GBM was 26.5 and
18 months, respectively (HR 0.45; P = .003). Moreover, EGFR/ERBB alterations were associated with favorable
outcome (HR of 0.37 (P = .003), but only in MGMT promoter unmethylated GBM. We further found that patients
with EGFR/ERBB alterations who also harbored PDGFRA amplification had a significantly worse outcome (HR 7.89;
P = .025).
Conclusions. Our data provide further insight into the impact of genetic alterations on various clinical outcomes
in IDHwt GBM in 2 cohorts of patients with detailed clinical information and inspire new therapeutic strategies for
IDHwt GBM.

Key Points
• In our analysis of 2 cohorts of IDHwt GBM, EGFR/ERBB alterations were associated with
favorable outcome in MGMT promoter unmethylated GBM.
• Patients with EGFR/ERBB alterations who also harbored PDGFRA amplification had
significantly worse outcome.
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Importance of the Study

Gliomas are tumors that arise from the glial cells in the
central nervous system. Glioblastoma (GBM) is the most
common malignant glioma and represents astrocytoma
grade IV.1 Despite our deeper understanding of the genomic alterations that precipitate gliomagenesis, only a few
genetic and epigenetic modifications have been identified
to be meaningful in clinical practice: At the chromosomal
level, simultaneous copy number losses of chromosomes
1p and 19q—based on the World Health Organization 2016
classification of brain tumors—define oligodendrogliomas.2
Oligodendrogliomas have better survival outcomes compared to astrocytomas.3,4 Similarly, it is well established
that isocitrate dehydrogenase (IDH) 1 and 2 mutations carry
favorable outcomes in patients with astrocytomas and secondary GBM.5 Finally, the promoter methylation status of
the gene encoding for the repair enzyme O6-methylguanineDNA methyltransferase (MGMT) predicts response to the
standard-of-care alkylating chemotherapy agent used in
glioma: temozolomide.6
Besides tumor-treating fields, little progress has been
made in the management of GBM over the past 2 decades
despite enormous research efforts. In fact, GBM was the
first cancer type to be analyzed by The Cancer Genome
Atlas (TCGA) project which revealed several genomic subtypes of the tumor.7 Genomic alterations—including copy
number variations (CNV) and mutations—lead to activation of oncogenes and inactivation of tumor suppressor
genes. Hence, we now better understand the various
cellular mechanisms and pathways utilized by gliomas
for growth and survival. The most common altered pathways in GBM include: receptor tyrosine kinase (RTK/
RAS) pathway (eg, via amplification of epidermal growth
factor receptor [EGFR] and platelet-derived growth factor
receptor [PDGFR]), phosphatidylinositol 3-kinase (PI3K)
pathway (eg, via deletion of the tumor suppressor [PTEN]),
cell cycle pathway (eg, via mutations in CDKN2A/B and
RB1), P53 pathway (eg, via mutations in P53 and MDM2),
and telomere length maintaining pathways (eg, TERT promoter mutations).8
Targeted therapies emerged to tackle specific pathways
utilized by cancer cells. While these treatments have had
successes in cancers such as melanoma and non-smallcell lung cancer, clinical trials of small molecule inhibitors, antibodies, vaccines, and kinase inhibitors targeting
these pathways have not improved overall survival (OS)
in patients with GBM. A key reason for failure of target
inhibition in gliomas appears to be tumor heterogeneity
and cancer cell plasticity leading to redundant inputs that

CLIA-certified molecular sequencing tests for
patients with IDH-wild-type glioblastoma at the
Ohio State University. We correlate mutations
and genetic alterations with various clinical
endpoints in patients from our cohort as well
as a publically available cohort from MemorialSloan Kettering Cancer Center.

maintain the downstream signaling pathways allowing the
cancer cells to survive even if one upstream signaling receptor is blocked.9
In this study, we aimed to correlate genomic alterations
with clinical patient outcomes in 2 cohorts of IDHwt GBM
and to assess interactions among the various alterations.

Methods
Under an IRB-approved protocol, we compiled a comprehensive clinically annotated database of adult patients
with GBM at The Ohio State University (OSU) for whom
we had next-generation sequencing (NGS) data through
CLIA-certified commercial platforms (Foundation One
and Tempus). The database included information detailing
the pathologic diagnosis, age, race, gender, performance
status, tumor location, treatments utilized, occurrence of
complications (radiation necrosis, leptomeningeal spread,
or thromboembolic disease defined as deep vein thrombosis and/or pulmonary embolism at any time during the
disease course), molecular classifications (IDH mutations,
MGMT promoter methylation, 1p19q co-deletion), programmed death ligand-1 (PD-L1) protein expression on
immunohistochemistry, and survival data, in addition to
NGS data.
Furthermore, we added publicly available data from a
cohort of IDH-wild-type (IDHwt) GBM from Memorial Sloan
Kettering Cancer Center (MSKCC)10 through cBioPortal.11,12
We also acquired MGMT promoter methylation data for
this cohort from MSKCC as this data was not available
through cBioPortal. The aim was to correlate mutational
data with clinical outcomes, namely OS. Each of the mutations/alterations served as a variable in univariate and multivariate analyses.
We grouped certain alterations under one variable based
on the core signaling pathway altering functions.8 The molecular variables included are listed in Table 1.

Statistical Analysis
A Cox’s proportional hazards model was used for univariate and multivariate survival analyses. Backward stepwise
regression models were used when looking at subgroups
to decrease the number of variables in smaller cohorts.
Chi-square tests were used for categorical variables.
A nonparametric test was used to compare the median
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In the era of personalized medicine, it has become routine practice to sequence tumors to
aide in decisions making regarding treatment
options, either for the sake of clinical trials inclusion, or for salvage treatment for patients
who have exhausted standard-of-care options.
In this paper, we report our experience with
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Mutations/Alterations

MDM/TP53

MDM2, MDM4 or TP53 mutations

CDKN2A/B

CDKN2A/B/C deletions or mutations (rare)

CDK/CCND

CDK4/CDK6 amplifications, or
CCND1/CCND2 amplifications

RB1

RB1 mutations/deletions

EGFR/ERBB

EGFR amplifications/mutations or ERBB
(2-4) mutations.

FGFR

FGFR mutations/amplifications

PDGFRA/KIT

PDGFRA mutations/amplifications

NF1

NF1 mutations

PTEN

PTEN mutations/deletions

PIK3R1

PIK3R1 mutations/deletions

PI3K gain

PIK3CA mutations, mTOR mutations or
AKT amplifications

MYC

MYC: MYC/MYCN amplifications

TERT

TERT promoter mutations

Results
Patient Characteristics
Of the 73 patients with IDHwt GBM from the OSU cohort
included in the study, MGMT promoter methylation data
was available on 68/73 patients and these patients were included in the survival analysis. Similarly, we were able to
obtain MGMT promoter methylation data on 107/204 patients from the MSKCC cohort. Only patients with known
MGMT promoter methylation status were included in this
analysis as we figured that any model that does not include MGMT would be inaccurate. Figure 1 shows a flow
diagram of the analyses performed on each or both cohorts and number of patients included in each analysis.
The median age for the OSU cohort was 60 years (20–78)
and the median age for the MSKCC cohort was 61 years
(22–91; P = .649). The median OS for the OSU cohort of
20.88 months (95% CI, 15.88–25.87) was similar to that for the
MSKCC cohort of 18.77 months (95% CI, 16.46–21.08; P = .464).

  

  

Available MGMT data

Figure 1.
  

OSU cohort (N = 73)

MSKCC cohort (N = 204)

OSU cohort (N = 68)

MSKCC cohorts (N = 107)

Survival analysis

Both cohorts (n = 175)

Stability of genomic
alterations

Both cohorts (n = 22)

Survival data including
extent of resection

OSU cohort (N = 62)

Cerebral necrosis

OSU cohort (N = 15/63)

Leptomeningeal spread

OSU cohort (N = 5/65)

A flow diagram showing the analyses performed on the OSU and MSKCC cohorts and number of patients included in each analysis.
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Variable

age for the 2 cohorts as age was not normally distributed P
values less than .05 were considered significant. IBM SPSS
Statistics 26 was used.
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Table 1. Variables Included in the Univariate and Multivariate
Survival Models Grouped Based on Function in the Core Signaling
Pathways
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Genomic Alterations and Overall Survival (both
cohorts)
A total of 175 patients were included in this analysis. Results
of the univariate and multivariate analyses are shown inTable
2. As expected, MGMT promoter methylation was significantly associated with improved OS. Median OS for methylated and unmethylated MGMT promoter GBM were 26.5

OSU+MSK with
MGMT (N = 175)

Univariate
Analysis
P value (HR)

Multivariate Model
(0.001)- P value
(HR)

Age

.619

.793 (1.003)

MGMT

.008 (0.53)

.003 (0.45)

MDM/P53

.507

.023 (0.49)

CDKN2A/B

.765

.388

CDK/CCND

.706

.985

RB1

.145

.06 (0.367)

EGFR/ERBB

.003 (0.49)

.0002 (0.31)

FGFR

.568

.378

PDGFRA/KIT

.941

.974

NF1

.208

.641

PTEN

.026 (1.66)

.513

PIK3R1

.936

.067 (0.38)

PI3K gain

.386

.281

MYC

.988

.183

TERT promoter

.043 (1.93)

.074 (2.07)

and 18 months, respectively (multivariable HR 0.45; P = .003).
Unexpectedly, EGFR/ERBB alterations were also associated
with significantly improved OS. OS for EGFR/ERBB altered
GBM and EGFR/ERBBwt GBM were 24.95 and 16.86 months,
respectively (multivariable HR 0.31; P < .001). EGFR amplification, specifically, was also associated with improved OS
(multivariable HR 0.41; P = .009).
Favorable survival related to EGFR/ERBB alterations
appeared to hold true only when MGMT promoter was
unmethylated: in a backward stepwise regression model
(P = .003) of the 112 unmethylated MGMT promoter cohort,
EGFR/ERBB alterations were associated with favorable HR of
0.37 (P = .003; Figure 2). Median OS for MGMT unmethylated,
EGFR/ERBB altered GBM was 25.05 months compared
to 15.12 months for MGMT unmethylated, EGFR/ERBBwt
GBM. In patients with unmethylated MGMT promoter GBM,
MDM/P53 alterations were also associated with favorable outcome (HR 0.51; P = .027). On the other hand, when MGMT promoter was methylated (N = 63), a backward stepwise model
(P = .001) revealed FGFR and PTEN as markers of worse survival (HR 10.23; P = .001 and HR 3.02; P = .012, respectively).

Association Between EGFR/ERBB and PDGFRA
Amplification
The multivariable analysis hinted at an association between EGFR/ERBB and PDGFRA. We therefore performed
separate analyses for patients who were positive for
EGFR/ERBB alterations (N = 78; Table 3) and those were
not. In patients with EGFR/ERBB alterations (or those who
specifically had EGFR amplification), univariate and multivariate analyses showed that those who also had PDGFRA
(N = 5) amplification had significantly worse survival (multivariate HR 7.89; P = .025; Figure 3). Median OS for patients

  
  

Survival Function at mean of covariates
EGFR/ERBB
0
1

1.0

0.8

0.6

0.4

0.2

0.0
.00

20.00

40.00
Survival (months)

60.00

Figure 2. The presence of EGFR/ERBB alterations was associated with favorable outcome in a cohort of 112 patients with unmethylated MGMT
promoter GBM.
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Table 2. Univariate and Multivariate Analyses Correlating the
Various Genomic Alterations With Overall Survival

Cum Survival
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Multivariate Model
(0.023)- P
value (HR)

Age

.261

.120

MGMT

.224

.241

MDM/P53

.520

.317

CDKN2A/B

.434

.505

CDK/CCND

0.742

.976

RB1

.686

.878

FGFR

.495

.981

PDGFRA/KIT

.034 (3.86)

.025 (7.89)

NF1

.361

.877

PTEN

.01 (2.60)

.454

PI3K gain

.112

.175

MYC

.196

.721

TERT promoter

.031 (5.17)

.139

Overall survival
Looking at the OSU cohort alone, we were able to incorporate extent of resection into the model (N = 62).
A strongly significant backward stepwise regression model (P < .001) revealed that extent of resection
(P = .023), MGMT (HR 0.54; P = .086), and EGFR/ERBB
alterations (HR 0.31; P = .003) correlate with significant
favorable outcomes. Biopsy only compared to gross
total resection carried significantly worse outcome (HR
4.97; P = .006). Subtotal was not significantly different
from gross total resection in the multivariate model.
Also, of note, presence of thromboembolic disease was
also associated with worse OS in the OSU cohort in univariate but not multivariate analysis (univariate HR 2.26;
P = .009).

Progression-free survival
A strongly significant backward stepwise model (P < .001)
revealed extent of resection (P = .022), MGMT promoter
methylation (HR 0.29; P < .001), EGFR/ERBB alterations
(HR 0.40; P = .011), CDKN2A/B loss (HR 0.39; P = .012),
and PIK3R1 mutations (HR 0.04; P = .003) as significant

  
  

Survival Function at mean of covariates
1.0

PDGFRAwt
PDGFRAamp

Cum Survival

0.8

0.6

0.4

0.2

0.0
.00

Figure 3.
  

20.00

40.00
Survival (months)

60.00

The presence of PDGFRA amplification in EGFR/ERBB altered GBM was associated with worse survival in a cohort of 78 patients.

Downloaded from https://academic.oup.com/noa/article/3/1/vdab127/6378698 by Thomas Jefferson University user on 05 April 2022

Univariate
Analysis
P value (HR)

Four patients from the OSU cohort and 22 patients from
the MSKCC cohort had DNA sequencing performed on
recurrent samples. CDKN2A/B, EGFR, TP53, and PTEN alterations were most consistent between the primary and
recurrent samples (Figure 4).

Genomic Alterations and Clinical Outcomes
(OSU cohort)

  
Table 3. Univariate and Multivariate Analyses Correlating
the Various Genomic Alterations With Overall Survival Within
EGFR/ERBB Altered Tumors
OSU+MSK with MGMT
(EGFR/ERBB altered) (N = 78)

Stability of Genomic Alterations Across
Recurrent Samples

Neuro-Oncology
Advances

who were positive for EGFR/ERBB alterations and PDGFRA
amplification was 18.44 m compared to 34.06 m for patients positive for EGFR/ERBB alterations without PDGFRA
amplification.
In patients without EGFR/ERBB alterations, a backward
stepwise model (P = .008), revealed only MGMT promoter
methylation as a favorable marker (HR 0.45; P = .023). Age
was associated with worse outcome (HR 1.02; P = .047).

5

OSU-106

P-0003598

OSU-98

OSU-18

OSU-10

P-0007917

P-0006416

P-0006045

P-0004778

P-0002265

P-0002181

  
P-0001843

P-0001731

P-0007010

P-0006970

P-0005615

P-0003693

P-0002647

P-0001654

P-0000883

P-0000758
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P-0000657

6

mutation

deep del

amplification

mut+amp

Figure 4. Mutations and copy number variations in primary and recurrent samples for each patient are shown in pairs. MSKCC patient IDs are as
identified in cBioPortal.
  

favorable outcomes. Biopsy only as opposed to gross total
resection carried significantly worse risk of progression
(HR 3.627; P = .007).

Cerebral necrosis
Treatment-related cerebral necrosis is a potential complication in patients with gliomas. Information about cerebral necrosis was available on 63 patients. Nine out of 24
(37.5%) of patients with methylated MGMT promoter GBM
developed RN versus 6/39 (15.4%) in the unmethylated
group. Chi-square test (P = .045).

Leptomeningeal spread
Five out of 65 (7.7%) patients (with available data) developed leptomeningeal disease (LMD). All tumors appeared
to have extended into the ventricles on brain imaging by
the time of development of LMD. Four tumors had evidence of subependymal spread prior (range 45–93 days)
to development of LMD. Four patients had available
CSF studies, 2 of whom had evidence of atypical or malignant cells. CSF protein was elevated in all 4 samples
(range 113–492 mg/dL). CSF glucose was low in all 4 samples (range < 10–46 mg/dL). MGMT promoter was methylated in 2 tumors and unmethylated in 2 and unknown
in 1. The genomic alterations varied among samples and
included EGFR V765M mutation (N = 1), PDGFRA amplification (N = 1), PDGFRA Y849C subclonal mutation (N = 1),
CDKN2A/B loss (N = 2), TP53 mutations (N = 3), and TERT
promoter mutations (N = 3). No case had EGFR amplification or EGFRvIII mutation. Other alterations observed
included DNMT3A mutation, KIT, MYC, and MDM2 amplifications and RB1 losses. PD-L1 expression in tumor samples ranged from 5% to 40%. One intracranial sample had
a 20% PD-L1 expression with LMD from this tumor exhibiting 40% PD-L1 expression. Median OS was 11.67 months
(range 6.05–18.31). Median OS after LMD diagnosis was
2.76 months (range 1.91–7.39).

Discussion
We compiled a comprehensive clinically annotated database of with detailed demographic and clinical data of
73 patients with IDHwt GBM. We then added data that is
publicly available from MSKCC through cBioPortal. This
cohort included 204 patients with IDHwt GBM. The aim
was to correlate different mutational data with clinical outcomes, namely survival. Each of the mutations/alterations
served as a variable in univariate and multivariate analyses. Survival analyses were performed on 175 patients
for whom MGMT promoter methylation status is known.
As expected, MGMT promoter methylation was significantly associated with better outcome HR 0.45; P = .003.
Furthermore, GBM with EGFR/ERBB alterations (and specifically EGFR amplification) had better outcome compared to
EGFR/ERBBwt GBM. However, this appeared to be true only
in MGMT promoter unmethylated GBM. Previous literature is
unclear in prognostic role of EGFR in GBM, as some studies
suggested favorable outcome and others suggested worse
outcome.13,14 However, to our knowledge this has not been
looked at previously in the setting of multivariable analysis
and specifically MGMT promoter methylation. This finding
will need to be validated in bigger datasets.
In the OSU cohort alone, more aggressive surgical resection, MGMT promoter methylation and EGFR/ERBB alterations yielded favorable OS and PFS outcomes. Moreover,
focusing on patients with EGFR/ERBB alterations, in both
cohorts, univariate and multivariate analysis showed an
association between EGFR and PDGFRA. More specifically,
patients with an EGFR/ERBB alteration who also exhibited
PDGFRA amplification had significantly worse survival (HR
7.89; P = .025) hinting to a potential interaction between the
2 receptors that needs further evaluation.
PDGFRα and PDGFRβ (encoded by PDGFRA and PDGFRB,
respectively) are both expressed as transmembrane receptors on GBM cell surface and are drivers of glioma growth.
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PDGFRA amplification is the more common alteration and
occurs in 13.1% of GBM.7 While concurrent amplification of
EGFR and PDGFRA has been reported in up to 5% of GBM,7
EGFR and PDGFRA co-expression at the mRNA level is seen
in 37% of GBM sphere lines as reported by Chakravarty et al.15
The paper also showed functional transactivation of PDGFRα
by EGFR: EGF stimulation in this setting can result both in
EGFR-EGFR homodimerization as well as EGFR-PDGFRα
heterodimerization which can drive proliferation.15 Further
supporting this interaction, Hegi et al. observed that the expression of p-EGFR correlated with p-PDGFRβ in a window
of opportunity study of 22 patients with recurrent GBM who
were treated with at least 5 days of gefitinib (an EGFR inhibitor) prior to re-resection.16 We believe that the interaction between EGFR and PDGFRA alterations may have therapeutic
implications and escaping to PDGFR signaling may in part explain the failure of EGFR targeted therapy in GBM.
Tumor heterogeneity and multiple RTK pathway activation have rendered GBM highly resistant to targeted treatment,17 particularly in the recurrent setting. GBM has been
reported to change methylation subclass upon recurrence,
which may further point to emergence of adaptive resistance mechanisms to therapy.18 Likewise, EGFR amplification has been previously reported to be lost in 16–27% of
recurrent samples.18,19 We illustrate how CDKN2A/B, EGFR,
TP53, and PTEN alterations were most consistent between
the primary and recurrent samples, however, none of the
mutations/copy number variations appear to be invariably
consistent between the primary and recurrent samples.
As previously described,20 MGMT promoter methylation
was associated with increased risk of treatment related cerebral necrosis: (37.5%) versus (15.4%) in the methylated
and unmethylated groups, respectively, in the OSU cohort. Furthermore, GBM patients who developed leptomeningeal disease had no one consistent genetic alteration.
Rather, in all instances, the lesions had extended toward
the ventricles prior to development of LMD.
In summary, NGS provides valuable information when
caring for patients with GBM. The study is limited by the
small sample size, especially for the analyses performed
on the OSU cohort alone, leading to low power to make
definitive statistical conclusions. The study is also limited
by the fact that glioblastoma was diagnosed solely based
on pathologic evaluations; new diagnostic entities have
been established based on methylation testing.21 The study
is rather hypothesis generating and our findings will need
validation from other bigger cohorts. We find that MGMT
unmethylated GBM that harbors EGFR/ERBB alterations
appear to have better prognosis in comparison to MGMT
unmethylated EGFR/ERBBwt tumors. Moreover, there appears to be a significant interaction between EGFR and
PDGFRA. This may in part explain EGFR inhibition resistance in GBM and highlights the plasticity of GBM cells.
Combining targeted treatments against these 2 receptors
may be an attractive therapeutic target.
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